Perioperative management of patients on chronic antithrombotic therapyORTEL, Thomas L.Blood. 2012, Vol 120, Num 24, pp 4699-4705, issn 0006-4971, 7 p.Article

Clinical implications for patients on antithrombotic therapy while taking supplementsORTEL, Thomas L.Thrombosis research. 2005, Vol 117, Num 1-2, pp 75-80, issn 0049-3848, 6 p.Conference Paper

Pathophysiology and laboratory testing of heparin-induced thrombocytopeniaCHONG, B. H; EISBACHER, M.Seminars in hematology. 1998, Vol 35, Num 4, pp 3-8, issn 0037-1963, SUP5Conference Paper

Limitations of conventional treatment options for heparin-induced thrombocytopeniaWARKENTIN, T. E.Seminars in hematology. 1998, Vol 35, Num 4, pp 17-25, issn 0037-1963, SUP5Conference Paper

Acquired thrombotic risk factors in the critical care settingORTEL, Thomas L.Critical care medicine. 2010, Vol 38, Num 2, issn 0090-3493, S43-S50, SUPArticle

Recent developments in topical thrombinsKESSLER, Craig M; ORTEL, Thomas L.Thrombosis and haemostasis. 2009, Vol 102, Num 1, pp 15-24, issn 0340-6245, 10 p.Article

Von Willebrand's disease diagnosed after menorrhagia worsened from levonorgestrel intrauterine systemLUKES, Andrea S; PERRY, Stephanie; ORTEL, Thomas L et al.Obstetrics and gynecology (New York. 1953). 2005, Vol 105, Num 5, pp 1223-1226, issn 0029-7844, 4 p., 2Article

Prothrombin and β₂-glycoprotein I frequently contribute to antiphospholipid antibody interactions with phospholipids and the generation of abnormal waveform profiles in coagulation assaysZUOWEI SU; IZUMI, Tomonori; ORTEL, Thomas L et al.Thrombosis and haemostasis. 2003, Vol 90, Num 2, pp 218-226, issn 0340-6245, 9 p.Article

Point-of-care testing of the international normalized ratio in patients with antiphospholipid antibodiesPERRY, Stephanie L; SAMSA, Gregory P; ORTEL, Thomas L et al.Thrombosis and haemostasis. 2005, Vol 94, Num 6, pp 1196-1202, issn 0340-6245, 7 p.Article

Binding of factor VIII inhibitors to discrete regions of the factor VIII C2 domain disrupt phospholipid bindingLEWIS, Deborah A; MOORE, Karen D; ORTEL, Thomas L et al.Blood coagulation & fibrinolysis. 2003, Vol 14, Num 4, pp 361-368, issn 0957-5235, 8 p.Article

Contributions of Asn²¹⁹⁸, Met²¹⁹⁹, and Phe²²⁰⁰ in the factor VIII C2 domain to cofactor activity, phospholipid-binding, and von Willebrand factor-bindingLEWIS, Deborah A; POUND, Mary L; ORTEL, Thomas L et al.Thrombosis and haemostasis. 2003, Vol 89, Num 5, pp 795-802, issn 0340-6245, 8 p.Article

Clinical and laboratory evaluation of thrombophiliaPERRY, Stephanie L; ORTEL, Thomas L.Clinics in chest medicine. 2003, Vol 24, Num 1, pp vii-viii, issn 0272-5231, 19 p.Article

Issues in the utilization of low molecular weight heparinsO'SHEA, Susan I; ORTEL, Thomas L.Seminars in hematology. 2002, Vol 39, Num 3, pp 172-178, issn 0037-1963Article

New treatment options for heparin-induced thrombocytopeniaORTEL, T. L; CHONG, B. H.Seminars in hematology. 1998, Vol 35, Num 4, pp 26-34, issn 0037-1963, SUP5Conference Paper

Performance of a new, rapid, automated immunoassay for the detection of anti-platelet factor 4/heparin complex antibodiesDAVIDSON, Simon J; ORTEL, Thomas L; SMITH, Larry J et al.Blood coagulation & fibrinolysis. 2011, Vol 22, Num 4, pp 340-344, issn 0957-5235, 5 p.Article

Comparative Effectiveness of Warfarin and New Oral Anticoagulants for the Management of Atrial Fibrillation and Venous Thromboembolism: A Systematic ReviewADAM, Soheir S; MCDUFFIE, Jennifer R; ORTEL, Thomas L et al.Annals of internal medicine. 2012, Vol 157, Num 11, pp 796-807, issn 0003-4819, 12 p.Article

Plasmapheresis and Heparin Reexposure as a Management Strategy for Cardiac Surgical Patients with Heparin-Induced ThrombocytopeniaWELSBY, Ian J; UM, John; MILANO, Carmelo A et al.Anesthesia and analgesia. 2010, Vol 110, Num 1, pp 30-35, issn 0003-2999, 6 p.Article

Frequency of anti-heparin-platelet factor 4 antibodies in hemodialysis patients and correlation with recurrent vascular access thrombosisO'SHEA, Susan I; SANDS, Jeffrey J; NUDO, Sybil A et al.American journal of hematology. 2002, Vol 69, Num 1, pp 72-73, issn 0361-8609Article

Anti-β₂-glycoprotein I antibody-mediated inhibition of activated protein C requires binding of β₂-glycoprotein I to phospholipidsIZUMI, Tomonori; POUND, Mary L; ZUOWEI SU et al.Thrombosis and haemostasis. 2002, Vol 88, Num 4, pp 620-626, issn 0340-6245, 7 p.Article

Mutation of MYH9, encoding non-muscle myosin heavy chain A, in May-Hegglin anomalyKELLEY, Michael J; JAWIEN, William; ORTEL, Thomas L et al.Nature genetics. 2000, Vol 26, Num 1, pp 106-108, issn 1061-4036Article

Hypercoagulable states and antithrombotic strategies in recurrent vascular access site thrombosisO'SHEA, Susan I; LAWSON, Jeffrey H; REDDAN, Donal et al.Journal of vascular surgery. 2003, Vol 38, Num 3, pp 541-548, issn 0741-5214, 8 p.Article

A multi-dose pharmacokinetic study of dalteparin in haemodialysis patientsPERRY, Stephanie L; O'SHEA, Susan I; BYRNE, Stephen et al.Thrombosis and haemostasis. 2006, Vol 96, Num 6, pp 750-755, issn 0340-6245, 6 p.Article

Phospholipid vesicles interfere with the binding of antibody fragments to the light chain of factor VIIILEWIS, Deborah A; BOVENSCHEN, Niels; MERTENS, Koen et al.Thrombosis and haemostasis. 2005, Vol 93, Num 5, pp 833-841, issn 0340-6245, 9 p.Article

Risk factors associated with thrombosis in patients with antiphospholipid antibodiesHANSEN, Karen E; KONG, David F; MOORE, Karen D et al.Journal of rheumatology. 2001, Vol 28, Num 9, pp 2018-2024, issn 0315-162XArticle

Assays for Measuring Rivaroxaban: Their Suitability and LimitationsLINDHOFF-LAST, Edelgard; SAMAMA, Meyer Michel; ORTEL, Thomas L et al.Therapeutic drug monitoring. 2010, Vol 32, Num 6, pp 673-679, issn 0163-4356, 7 p.Article